Cite
Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
MLA
Gandemer, Virginie, et al. “Clinical Value of Pre-Transplant Minimal Residual Disease in Childhood Lymphoblastic Leukaemia: The Results of the French Minimal Residual Disease-Guided Protocol.” British Journal of Haematology, vol. 165, no. 3, May 2014, pp. 392–401. EBSCOhost, https://doi.org/10.1111/bjh.12749.
APA
Gandemer, V., Pochon, C., Oger, E., Dalle, J. H., Michel, G., Schmitt, C., Berranger, E., Galambrun, C., Cavé, H., Cayuela, J., Grardel, N., Macintyre, E., Margueritte, G., Méchinaud, F., Rorhlich, P., Lutz, P., Demeocq, F., Schneider, P., Plantaz, D., & Poirée, M. (2014). Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol. British Journal of Haematology, 165(3), 392–401. https://doi.org/10.1111/bjh.12749
Chicago
Gandemer, Virginie, Cécile Pochon, Emmanuel Oger, Jean‐Hugues H. Dalle, Gérard Michel, Claudine Schmitt, Eva Berranger, et al. 2014. “Clinical Value of Pre-Transplant Minimal Residual Disease in Childhood Lymphoblastic Leukaemia: The Results of the French Minimal Residual Disease-Guided Protocol.” British Journal of Haematology 165 (3): 392–401. doi:10.1111/bjh.12749.